HHCP
TAK icon

Hilton Head Capital Partners’s Takeda Pharmaceutical TAK Stock Holding History

Hilton Head Capital Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61K Hold
163
– – ﹤0.01% 750
2026
Q1 		$3.02K Hold
163
– – ﹤0.01% 744
2025
Q4 		$2.54K Buy
+163
New +$2.33K ﹤0.01% 732

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Hilton Head Capital Partners's TAK Position: Q2 2026 in Review

Hilton Head Capital Partners held its Takeda Pharmaceutical (TAK) position steady in Q2 2026 at 163 shares worth $2.61K. The position accounts for ﹤0.01% of the portfolio, ranked #750.

Hilton Head Capital Partners first reported a position in TAK in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.02K in Q1 2026. 375 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Hilton Head Capital Partners held 163 shares of Takeda Pharmaceutical worth $2.61K as of Q2 2026.
  • Hilton Head Capital Partners left its Takeda Pharmaceutical share count unchanged in Q2 2026.
  • Takeda Pharmaceutical made up ﹤0.01% of Hilton Head Capital Partners's portfolio in Q2 2026, its #750 holding.
  • Hilton Head Capital Partners first reported a position in Takeda Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • Hilton Head Capital Partners's Takeda Pharmaceutical position peaked at $3.02K in Q1 2026.
  • 375 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.